Chief Science Officer & Director @ GBS Global Biopharma, Inc.
GB Sciences, Inc. @
Board Member @ Center for Healthcare Innovation
University of Southern California
Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc. Dr. Small-Howard had previously held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development
Dr. Andrea Small-Howard leverages broad biopharmaceutical industry knowledge and contacts in her current dual roles as the Chief Science Officer and member of the Board of Directors at GB Sciences, Inc. Dr. Small-Howard had previously held management positions at AMDL, Inc. (a small public biotech company), where she took the lead in every stage of product development from discovery through commercialization. As Vice President of Scientific Oversight at Radient Pharmaceuticals Corp., she provided strategic technical and regulatory oversight for global product development in multiple international business divisions. She founded International Biotechnology Solutions in 2011 to provide management consulting with a focus on assisting US biotech companies with products that could be commercialized within the Asia-Pacific region. In her consulting, she had successfully completed projects within the areas of business development, corporate alliance building, product commercialization, due diligence reporting on medical marijuana companies, corporate restructuring, and management of successful fund raising campaigns. Currently, she also serves on the Board of Directors for the Center for Healthcare Innovation based in Chicago, IL.
Dr. Small-Howard originally received her AB from Occidental College (Magna Cum Laude, Phi Beta Kappa), and both an MBA (Beta Gamma Sigma) and a PhD (USC All University Merit Fellow) in Biological Sciences from the University of Southern California. As a post-doctoral fellow at the Queens Medical Center in Honolulu, Hawaii, Dr. Small-Howard lead a project group dedicated to the study of cannabinoids in the immune system and published two peer reviewed papers on the subject. She brings to GB Sciences, Inc. a passion for advancing clinical research on the effectiveness of medical marijuana and will be a dedicated member of the GrowBLOX team.
Chief Science Officer @ GrowBLOX Sciences, Inc. (OTCQB: GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology for streamlining cannabis industry processes, and a "big" data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS Puerto Rico subsidiary, we are developing and globally distributing our GrowBLOX(TM) suite of cultivation and growing chambers. From June 2014 to Present (1 year 7 months) Board Member @ From June 2014 to Present (1 year 7 months) Board Member @ The Center for Healthcare Innovation is a non-profit, non-partisan, and independent organization committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation, particularly in the biotechnology, medical device, nanotechnology, and pharmaceutical sectors. The CHI vision is to become the world’s #1 independent thought-leadership institution and “think tank” for the global pharmaceutical and life sciences community. From January 2012 to Present (4 years) Greater Chicago AreaPresident @ International Biotechnology Solutions creates customized, cost-effective commercialization solutions for viable yet abandoned biopharma products. Based on our understanding that the paradigm by which biotechnology and pharmaceutical products reach the market has fundamentally changed, we explore new avenues to bring healthcare products to market in regions where there are unique needs. In particular, developing commercialization solutions to meet the needs of the healthcare market in the Asia-Pacific region can be more cost effective and may benefit a larger population. From July 2011 to November 2015 (4 years 5 months) Greater San Diego AreaBoard Member @ The Ceremax Investment Group was established by members of the USC EMBA Class XXV to pool its financial and intellectual resources to identify investment opportunities. Ceremax will capitalize on the collective experiences and pool of contacts of its members to source, underwrite, and manage these investment opportunities. Additionally, Ceremax will provide a channel for its members to strengthen the relationships first developed in the classroom while attending USC. From June 2011 to March 2013 (1 year 10 months) Vice President, Scientific Oversight @ • Provided oversight for global product development in multiple international business divisions
• Authored and/or attained 12 patents & 3 trademarks on proprietary cancer tests, cancer (gene) therapies, cosmeceuticals, and animal models
• Achieved numerous regulatory approvals for cancer tests, cancer therapies, pharmaceuticals, and cosmeceutical products with US FDA, Health Canada, Korean FDA, China SFDA, Taiwanese Ministry of Health, Indian Ministry of Health
• Initiated and/or nurtured 5 international, collaborative, cancer research trial programs with universities and hospitals studying colon, lung, and pancreatic cancer; as well as general cancer screening programs that yielded 7 publications supporting cancer products
• Championed Elleuxe®/Goodnak® cosmeceutical line
Provided oversight for formulations, safety & effectiveness testing, regulatory strategy
Led branding committee and created marketing materials with external agencies
Created commercialization strategy, sourced US raw materials, hired contract manufacturers
• Led and participated in internal and US FDA, CDPH, CE Mark/ISO 13485, and CMDR audits
• Advised CEO and CFO on Production Capacity and Supervised Quality System for ISO 13485 and cGMP compliant medical device manufacturing facility From November 2008 to July 2011 (2 years 9 months) Master of Business Admistration @ Beta Gamma Sigma International Honor Society From July 2009 to May 2011 (1 year 11 months) Director, Research, Development, Scientific Oversight @ • Championed DR-70® colorectal cancer test that accounts for 100% of domestic sales
Patented invention, performed clinical trials, obtained US FDA, KFDA, and CMDR approvals
Created commercialization strategy, advised on first exclusive distribution relationships, led branding committee, created marketing materials with the marketing department
• Designed commercialization strategy for in-licensed cervical cancer test, MyHPV Kit®
Developed technical product file in Korea with original manufacturer, created US prototype
Sourced US raw materials, hired contract manufacturers, prepared regulatory filings
• Represented company and promoted cancer tests at international cancer meetings
• Advised CEO on additional licensed technologies through due diligence research From July 2007 to November 2008 (1 year 5 months) Manager of Research & Development @ • Led medical device product development for colon, lung, pancreatic and general cancer tests with an annual budget of approximately $2.4 million USD
• Represented company regulatory filings directly with US FDA agency
• Managed intellectual property portfolio
• Achieved 28% decrease in production error rate through continuous process improvement program in manufacturing From February 2006 to July 2007 (1 year 6 months) Research Assistant Professor @ Responsibilities: in charge of research division devoted to the study of selenoprotein biosynthesis and role of selenoproteins in protection from oxidative damage.
Projects: identifying supramolecular complexes responsible for selenocysteine incorporation; demonstrating nucleo-cytoplasmic shuttling of selenium incorporation cofactors, defining the role of oxidative stress in neuronal neuropathies caused by elevated glucose levels, defining molecular responses to oxidative stress and links to oncological processes as well as protection from oxidative stress by selenoproteins. From June 2004 to January 2006 (1 year 8 months) Postdoctoral Research Fellow @ Principal Investigator: Helen Turner, Ph.D
Projects: the effects of cannabinoids on immune cells; oncogenic signaling by cigarette smoke condensates (CSC) in human mast cells; defining the calcium store operated transcriptome in mast cells From September 2001 to June 2004 (2 years 10 months) Graduate Researcher/Teaching Assistant @ Performed independent research; served as a teaching assistant in biochemistry (won teaching awards); molecular biology, and immunology. Gave guest lectures: 1) in the freshman biology class on plant physiology and 2) histology class on reproductive tissues and morphological/functional distinctions among gastrointestinal tissues. From August 1992 to May 1999 (6 years 10 months) Research Project Supervisor @ Principal Investigator: John S. Stephens, Ph. D
Occidental College, Los Angeles, CA 90041
The overall goal of the research project was to determine if thermal warming from the hydroelectric plant in King Harbor was having an effect on the local fauna, especially as it might have an impact on reef fish. Led monthly ichthyoplankton sample collections; supervised a team of biologists identifying fauna in the plankton trawls; and prepared monthly reports. In addition, created a dichotomous taxonomic tree for identifying the common (top 95% found in our collections) types of marine fish larvae. From September 1988 to May 1991 (2 years 9 months) Research Assistant @ Supervisor: Gary Jordan, M.A.
Occidental College, Los Angeles, CA 90041
Monitoring effects of sport fishing on fish stocks at the Salton Sea, California. From August 1987 to August 1988 (1 year 1 month)
MBA, Executive MBA, Class XXV @ USC Marshall School of Business From 2009 to 2011 Ph.D., Biochemistry, Molecular Biology, Immunology @ University of Southern California From 1992 to 1998 AB, Biology, Philosophy @ Occidental College From 1987 to 1991 Andrea MBA is skilled in: Medical Devices, Personalized Medicine, Biopharmaceuticals, Regulatory Submissions, Intellectual Capital Management, Medical Diagnostics, GMP, ISO 13485, CE marking, Biotechnology, FDA, Clinical Trials, Cancer, R&D, Molecular Biology
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension